The Cancer Research Institute offers scientists, researchers, clinicians, health care professionals, and others numerous resources to learn, understand, and collaborate on cutting-edge cancer immunotherapy advancements.
The International Cancer Immunotherapy Conference, hosted by the Cancer Research Institute (CRI), the European Network for Cancer Immunotherapy (ENCI), and the American Association of Cancer Research (AACR), is the reference meeting for immunotherapy scientists, clinicians, regulators, drug developers, and patient advocates. The program features talks from more than 50 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy, including: regulating T cells and their response to cancer, tumor microenvironment, genetically engineered T cells, maintenance of immune balance, novel vaccine platforms and combinations, mutational analysis and predicting response to immunotherapy, convergence of technology and cancer immunotherapy, microbiome, and metabolism. Continuing Medical Education Activity AMA PRA Category 1 Credits™ are available.
Register and Submit for CICON
Cancer Immunology Research publishes outstanding original articles reporting major advances in cancer immunology that span the discipline from basic investigations in host-tumor interactions to developmental therapeutics in model systems, early translational studies in patients, and late-stage clinical trials. The journal disseminates knowledge of immunology to the growing cancer research community, catalyzing cross-disciplinary work that yields a deeper understanding of the host-tumor relationship, more potent cancer treatments, and improved clinical outcomes.
Read Cancer Immunology Research
The Cancer Research Institute (CRI) iAtlas is an interactive web-based platform and set of analytic tools for studying interactions between tumors and the immune microenvironment. These tools allow researchers to explore associations among a variety of immune characterizations as well as with genomic and clinical phenotypes. The initial version of CRI iAtlas is based on an analysis performed by The Cancer Genome Atlas (TCGA) Research Network on the TCGA data set comprising over 10,000 tumor samples and 33 tumor samples (Thorsson et al. Immunity, 2018). In this analysis, each tumor sample was scored for a variety of readouts for immune response, such as immune cell composition, adaptive cell receptor repertoire, neoantigen load, and expression of genes coding for immunomodulatory proteins. The web tool allows research to explore these data readouts, and the relation between them in TCGA tumor types and in overarching immune subtypes identified in the study. The CRI iAtlas is made possible through collaboration between the Cancer Research Institute, Sage Bionetworks, and the Institute for Systems Biology. Moreover, the CRI iAtlas Targets module can now probe IO agent information in both the CRI Immuno-Oncology Landscape and the newly updated CRI Cancer Cell Therapy Landscape by respective gene.
Visit the CRI iAtlas
The database comprises more than 450 tumor antigenic peptides as well as publications describing a host of potential antigenic targets. The database is designed with the goal of being a useful tool for clinicians, therefore only the peptides that were fully validated have been include, and whose characterization was comprehensive and fully demonstrated the existence, nature, immunogenicity and the natural presentation of these antigenic peptides by tumor cells. Candidate peptides whose comprehensive characterization has not been reported are listed in an additional category of “potential peptides,” awaiting further characterization.
Visit the Peptide Database
Stay up to date on recent cancer immunotherapy news, discoveries, and breakthroughs with the Cancer Research Institute’s blog. Hear stories from the leading scientists in the field, patients whose lives have changed thanks to immunotherapy, and those that have joined CRI in supporting this innovative research. CRI's science writers provide daily recaps of AACR, ASCO, and CICON annual meetings and analyze new FDA approvals.
The Cancer Research Institute's Clinical Accelerator team presents an unbiased, neutral, scientifically curated, and timely updated analysis based on information collected from numerous trusted and publicly available sources.